Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2007-11-27
2007-11-27
Wehbe, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C530S387200
Reexamination Certificate
active
10819493
ABSTRACT:
The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals.
REFERENCES:
patent: 4349528 (1982-09-01), Koprowski et al.
patent: 4436728 (1984-03-01), Ribi et al.
patent: 4726947 (1988-02-01), Shimada et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5334708 (1994-08-01), Chang et al.
patent: 5407684 (1995-04-01), Loria et al.
patent: 5550026 (1996-08-01), Yamaguchi et al.
patent: 5977315 (1999-11-01), Chatterjee et al.
patent: 6235280 (2001-05-01), Chatterjee et al.
patent: 2002/0041872 (2002-04-01), Chatterjee et al.
patent: 2003/0077274 (2003-04-01), Chatterjee et al.
patent: WO-91/01990 (1991-02-01), None
patent: WO-91/11465 (1991-08-01), None
patent: WO-91/16924 (1991-11-01), None
patent: WO-92/16231 (1992-10-01), None
patent: WO-96/20219 (1996-07-01), None
patent: WO-96/20219 (1996-07-01), None
patent: WO-96/20277 (1996-07-01), None
patent: WO-96/20277 (1996-07-01), None
patent: WO-97/38725 (1997-10-01), None
Mittleman et al. (1994) Cancer Res., vol. 54, 415-421.
Sedlacek (1994) Crit. Rev. Oncogen., vol. 5 (6), 555-587.
Foon et al. (1995) J. Clin. Invest., vol. 96, 334-342.
Hinoda et al. (1995) Tumor Biol. 16, 48-55.
Herlyn et al. (1987) Proc. Natl. Acad. Sci., vol. 84, 8055-8059.
Bhattacharya-Chatterjee et al. (1987). “Idiotype Vaccines Against Human T Cell Acute Lymphoblastic Leukemia. I. Generation and Characterization of Biologicaly Active Monoclonal Anti-Idiotopes,”J. Immunol. 139(4):1354-1360.
Bhattacharya-Chatterjee et al. (1988). “Idiotype Vaccines Against Human T Cell Leukemia. II. Generation and Characterization of a Monoclonal Idiotype Cascade (Ab1, Ab2, and Ab3),”J. Immunol. 141(4):1398-1403.
Bhattacharya-Chatterjee et al. (1990). “Murine Monoclonal Anti-Idiotype Antibody as a Potential Network Antigen for Human Carcinoembryonic Antigen,”J. Immunol. 145(8):2758-2765.
Bhattacharya-Chatterjee et al. (1990). “Syngeneic Monoclonal Anti-Idiotype Antibody Related to Human Carcinoembryonic Antigen,”Proc. of the Amer. Assoc. Cancer Res. 31:279 (Abstract No. 1651).
Bhattacharya-Chatterjee et al. (1991). “Anti-Idiotype Monoclonal Antibodies as Vaccines for Human Cancer,”Intern. Rev. Immnunol. 7:289-302.
Bhattacharya-Chatterjee et al. (1991). “Idiotype Matching: Level of Expression of a Network Antigen Idiotype in Colon Cancer Patients' SERA,”FASEB J. 5(5):A1356 (Abstract No. 5713).
Bhattacharya-Chatterjee et al. (1993). “Idiotype Matching: A Network Antigen Idiotype is Expressed in Sera of Colon Cancer Patients,”Vaccine Research2(4):283-290.
Bhattacharya-Chatterjee et al. (1994) “Active Immunotherapy of Colorectal Cancer Patients with Murine Monoclonal Anti-Idiotype Antibody,”Proc. of Internatl. Cancer Congress, pp. 495-499.
Bhattacharya-Chatterjee, M. et al. (1994). “Idiotypic Antibody Immunotherapy of Cancer,”Cancer Immuno. Immunother. 38(2):75-82.
Bhattacharya-Chatterjee et al. (1994). “Murine Anti-Idiotype (Id) Monoclonal Antibody (mAb) Breaks Tolerance and Induces an Specific Antibody Response to Carcinoembryonic (CEA) in Colorectal Cancer (CRC) Patients,”FASEB J. 8(4):A200 (Abstract No. 1156).
Chakraborty et al. (1994). “Murine Monoclonal Anti-Idiotype Antibody Induces a Specific Antibody Response to Human Carcinoembryonic Antigen (CEA) in Cynomolgus Monkeys,”FASEB J. 8(4):A504 (Abstract No. 2917).
Chakraborty et al. (1995). “Preclinical Evaluation in Nonhuman Primates of an Anti-Idiotypic Antibody that Mimicks the Carcinoembryonic Antigen,”J. Immunother. 18(2):95-103.
Chatterjee, M. et al. (1993). “Antiidiotype (Ab2) Vaccine Therapy for Cutaneous T-Cell Lymphoma,”Ann. N. Y. Acad. Sci. 690:376-377.
Cheresh et al. (1986). “Biosynthesis and Expression of the Disialoganglioside GO2, a Relevant Target Antigen on Small Cell Lung Carcinoma for Monoclonal Antibody-Mediated Cytolysis”Cancer Res. 46:5112-5118.
DIALOG® Full Text of article, located in file 149 (TGG Health & Wellness DB(SM), written by Foon et al. (1996). “Anti-Idiotype Antibody Vaccine (3H1) the Mimics the Carcinoembryonic Antigen (CEA) as Adjuvant Treatment,”Proc. Annu. Meet. Am. Soc. Clin. Oncol., one page total.
DIALOG® Meeting Abstract, located in file 159 (CancerLit), written by Pervin et al. (1996). “Proliferation of T-Cells from Colon Cancer Patients by Peptides Based on the Structure of an Anti-Idiotype Antibody Mimicking CEA,”Proceedings of the Amer. Assoc. for Cancer ResearchWashington, D.C., one page total.
Erlichman et al. (1988). “A Randomized Trial of Fluorouracil and Folinic Acid in Patients with Metastatic Colorectal Carcinoma,”J. Clin. Oncol. 6(3):469-475.
Foon, K.A. et al. (1995). “Immune Response to the Carcinoembryonic Antigen in Patients Treated with Anti-Idiotype Antibody Vaccine,”J. Clin. Invest. 96:334-342.
Gennaro, A.R. ed. (1990).Remington's Pharmaceutical Sciences. 18th Edition (Table of Contents.).
Goldenberg, D.M. (1993). “Monoclonal Antibodies in Cancer Detection and Therapy,”Am. J. Med. 94(3):297-312.
Goodman, L.S. et al. eds. (1980). “Folic Acid,” Chapter 57in The Pharmacological Basis of Therapeutics. 6th Edition. Macmillan: New York. pp. 1340-1346.
Hansen, H.J. et al. (1989). “Solving the Problem of Antibody Interference in Commercial ‘Sandwich’-Type Immunoassays of Carcinoembryonic Antigen,”Clin. Chem. 35(1):146-151.
Hansen, H.J. et al. (1993). “Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen,”Cancer71(11):3478-3485.
Herlyn, D.M. et al. (1987). “Anti-Idiotype Immunization of Cancer Patients: Modulation of the Immune Response,”Proc. Natl. Acad. Sci. U.S.A. 84(22):8055-8059.
Hinoda, Y. et al. (1995). “Internal Image-Bearing Anti-Idiotypic Monoclonal Antibodies,”Tumor Biol. 16:48-55.
Honjo, T. et al. (1979). “Cloning and Complete Nucleotide Sequence of Mouse Immunoglobulin γ1 Chain Gene,”Cell18(2):559-568.
Irvine, K. et al. (1993). “Induction of Delayed-Type Hypersensitivity Responses by Monoclonal Anti-Idiotypic Antibodies to Tumor Cells Expressing Carcinoembryonic Antigen and Tumor-Associated Glycoprotein-72,”Cancer Immunol, Immunother. 36(5):281-292.
Jeme, N.K. (1974). “Towards a Network Theory of the Immune System,”Ann. Immunol. 125C(1-2):373-389.
Khazaeli, M.B. et al. (1988). “Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A. II,”J. Nat'l Cancer Inst. 80(12):937-942.
Kuroki, M. et al. (1992). “Biochemical Characterization of 25 Distinct Carcinoembryonic Antigen (CEA) Epitopes Recognized by 57 Monoclonal Antibodies and Categorized Into Seven Groups in Terms of Domain Structure of the CEA Molecule,”Hybridoma11(4):391-407.
Laemmli, U.K. (1970). “Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4,”Nature227:680-685.
Lindenmann, J. (1973). “Speculations on Idiotypes and Homobodies,”Ann. Immunol(Inst. Past) 124(2):171-184.
Losman, M.J. et al. (1994). “Mimicry of a Carcinoembryonic Antigen Epitope by a Rat Monoclonal Anti-Idiotype Antibody,”Int. J. Cancer56(4):580-584.
McBride W.H. et al. (1986). “Induction of Tolerance to a Murine Fibrosarcoma in Two Zones of Dosage-the Involvement of Suppressor Cells,”Br. J. Cancer53(6):707-711.
Mittelman, A. et al. (1992). “Human High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Induction of Humoral Anit-HMW-MAA Immunity and Prolongation of Survival in Patients with Stage IV Melanoma,”Proc. Natl. Acad. Sci. U.S.A. 89(2):466-470.
Mittelman, A. et al. (1994). “Kinetic
Chatterjee Malaya
Chatterjee Sunil K.
Foon Kenneth A.
Myers, Jr. Richard S.
Stites & Harbison PLLC
University of Kentucky Research Foundation
Wehbe Anne M.
Weyer Stephen
LandOfFree
Methods of delaying development of CEA-associated tumors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of delaying development of CEA-associated tumors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of delaying development of CEA-associated tumors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821667